

# Have We Reached an Estrogen Comfort Zone?

>> By Jill P. Buyon, MD

*This is a complete list of resources for "Have We Reached an Estrogen Comfort Zone?" To read the article, see the May 2007 issue, p. 1.*

## Resources:

- Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. *New Engl J Med.* 2005;353:2550-2558.
- Buyon JP, Petri M, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. *Ann Intern Med.* 2005;142:953-962.
- Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. *N Engl J Med.* 2005;353:2539-2549.
- Sanchez-Guerrero J, Karlson EW, Liang MH, Hunter DJ, Speizer FE, Colditz GA. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. *Arthritis Rheum.* 1997;40:804-808.
- Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study. *Arthritis Rheum.* 2002;46:1830-1839.
- Jungers P, Dougados M, Pelissier C, et al. Influence of oral contraceptive therapy on activity of systemic lupus erythematosus. *Arthritis Rheum.* 1982;25:618-623.
- Julkunen HA. Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE. *Scand J Rheumatol.* 1991;20:427-433.
- Buyon JP, Kalunian KC, Skovron ML, et al. Can women with systemic lupus erythematosus safely use exogenous estrogens? *J Clin Rheumatol.* 1995;1:205-212.
- Pando JA, Gourley MF, Wilder RL, Crofford LJ. Hormonal supplementation as treatment for cyclical rashes in patients with systemic lupus erythematosus. *J Rheumatol.* 1995;22:2159-2162.
- Petri M, Robinson C. Oral contraceptives and systemic lupus erythematosus. *Arthritis Rheum.* 1997;40:797-803.
- Suenaga R, Mitamura K, Evans MJ, Abdou NI. Binding affinity and quantity of estrogen receptor in peripheral blood monocytes of patients with systemic lupus erythematosus. *Lupus.* 1996;5:227-231.
- Suenaga R, Evans MJ, Mitamura K, Rider V, Abdou NI. Peripheral blood T cells and monocytes and B cell lines derived from patients with lupus express estrogen receptor transcripts similar to those of normal cells. *J Rheumatol.* 1998;25:1305-1312.
- Liu H, Liu Z, Chen Z, Liu D, Li L. [Estrogen receptor gene polymorphism and its association with clinicopathological manifestation of lupus nephritis.] *Zhonghua Yi Xue Yi Chuan Xue Za Zhi.* 2000;17:266-269.
- Peeva E, Venkatesh J, Michael D, Diamond B. Pro-lactin as a modulator of B cell function: implications for SLE. *Biomed Pharmacother.* 2004;58:310-319.
- Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. The Framingham study. *N Engl J Med.* 1987;317:1169-1174.
- Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, Mack TM. Menopausal estrogen therapy and hip fractures. *Ann Intern Med.* 1981;95:28-31.
- Ettinger B, Genant HK, Conn CE. Long-term estrogen replacement therapy prevents bone loss and fractures. *Ann Intern Med.* 1985;102:319-324.
- The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. *J Am Med Assoc.* 1996;276:1389-1396.
- Lufkin EG, Riggs BL. Three-year follow-up on effects of transdermal estrogen [letter]. *Ann Intern Med.* 1996;125:77.
- Pacifici R, Rifas L, McCracken R, et al. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin-1 release. *Proc Natl Acad Sci USA.* 1989;86:2398-2402.
- Jilka RL, Hangoc G, Girasole F, et al. Increased osteoclast development after estrogen loss-mediation by interleukin-6. *Science.* 1992;257:88-91.
- Gallagher JC, Riggs BL, Deluca HF. Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis. *J Clin Endocrinol Metab.* 1980;51:1359-1364.
- Ramsey-Goldman R, Dunn JE, Huang CF, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. *Arthritis Rheum.* 1999;42:882-890.
- Sinigaglia L, Varenna M, Binelli L, et al. Determinants of bone mass in systemic lupus erythematosus: a cross sectional study on premenopausal women. *J Rheumatol.* 1999;26:1280-1284.
- Gilboe IM, Kvien TK, Haugeberg G, Husby G. Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls. *Ann Rheum Dis.* 2000;59:110-115.
- Sowers MFR, Galuska DA. Epidemiology of bone mass in pre-menopausal women. *Epidemiol Rev.* 1993;15:374-398.
- American College of Rheumatology Task force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis Rheum.* 1996;39:1791-1801.
- FDA MedWatch 2004 Safety Alert – Depo-Provera (medroxyprogesterone acetate injectable suspension). <http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#Depo>
- Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. *J Am Med Assoc.* 1998;280:605-613.
- Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). *J Am Med Assoc.* 2002;288:49-57.
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. *J Am Med Assoc.* 2002;288:321-323.
- Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. *N Engl J Med.* 2003;349:2399-2406.
- Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. *N Engl J Med.* 2003;349:2407-2415.
- Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. *Am J Epidemiol.* 1997;145:408-415.
- Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S. Vascular stiffness in women with systemic lupus erythematosus. *Hypertension.* 2001;37:1075-1082.
- Nasr A, Breckwoldt M. Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of an iceberg. *Gynecol Endocrinol.* 1998;12:43-59.
- Jilka B, Hildebrandt J, Kapiotis S, et al. Effects of estradiol on circulating P-selectin. *J Clin Endocrinol Metab.* 1996;81:2350-2355.
- John S, Jacobi J, Schlaich MP, Delles C, Schmieder RE. Effects of oral contraceptives on vascular endothelium in premenopausal women. *Am J Obstet Gynecol.* 2000;183:28-33.
- Foegh ML, Zhao Y, Farhat M, Ramwell PW. Oestradiol inhibition of vascular myointimal proliferation following immune, chemical, and mechanical injury. *Ciba Foundation Symp.* 1995;191:139-145; discussion 145-149.
- Morris MS, Jacques FF, Selhub J, Rosenberg IH. Total homocysteine and estrogen status indicators in the Third National Health and Nutrition Examination Survey. *Am J Epidemiol.* 2000;152:140-148.
- Dubey RK, Tyurina YY, Tyurin VA, et al. Estrogen and tamoxifen metabolites protect smooth muscle cell membrane phospholipids against peroxidation and inhibit cell growth. *Circ Res.* 1999;84:229-239.
- Oparil S, Arthur C. Corcoran Memorial Lecture. Hormones and vasoprotection. *Hypertension.* 1999;33:170-176.
- Rosano GM, Caixeta AM, Chierchia S, et al. Short term anti ischemic effect of 17beta estradiol in postmenopausal women with coronary artery disease. *Circulation.* 1997;96:2837-2841.
- McHugh NA, Solowiej A, Klabunde RE, Merrill GF. Acute coronary vascular and myocardial perfusion effects of conjugated equine estrogen in the anesthetized dog. *Basic Res Cardiol.* 1998;93:470-476.
- Bellinger DA, Williams JK, Adams MR, Honore EK, Bender DE. Oral contraceptives and hormone replacement therapy do not increase the incidence of arterial thrombosis in a nonhuman primate model. *Arterioscler Thromb Vasc Biol.* 1998;18:92-99.
- Kaplan JR, Adams MR, Anthony MS, Morgan TM, Manuck SB, Clarkson TB. Dominant social status and contraceptive hormone treatment inhibit atherogenesis in premenopausal monkeys. *Arterioscler Thromb Vasc Biol.* 1995;15:2094-2100. **THE RHEUMATOLOGIST**

